Printer Friendly

GBP Deal of the Year Winners Emphasize Extent of Life Sciences Activity in Georgia.

ATLANTA, Jan. 23 /PRNewswire/ -- The Georgia Biomedical Partnership (GBP) announced six winners in four categories for the 2007 Deal of the Year awards. The deals reflect a broad range of activity, from university research to vaccine manufacturing, and demonstrate the diversity of Georgia's life sciences industry.

The Deal of the Year categories are Early Stage Financing; Strategic Transaction (Large Companies); Strategic Transaction (Small Companies); and Public Sector. Winners were selected from 11 finalists.

CardioMEMS and Metastatix won for Early Stage Financing; AtheroGenics and Solvay Pharmaceuticals, for Strategic Transaction (Large Company); GeoVax Labs, for Strategic Transaction (Small Company); and Emory University, Georgia Institute of Technology, and Medical College of Georgia, for the public sector. The winners were honored at the GBP's recent Awards Dinner at the Intercontinental Buckhead Hotel.

Metastatix, recognized for its $3.6 million Series A round, is an emerging cancer drug discovery company in Atlanta. The financing was led by H.I.G. Ventures and included the Aurora Funds, CM Capital Investments, SR One, and Medimmune Ventures. Existing investors, Georgia Venture Partners and Centrosome Ventures, along with the State of Georgia, also participated. Metastatix CEO Dr. Tony Shuker accepted the award.

CardioMEMS, recognized for its $22.6 million Series D round, is an Atlanta medical device company that applies microelectromechanical systems (MEMS) technology for the diagnosis, treatment and management of serious chronic diseases. Its first product is a wireless, implantable pressure monitor for human use. The financing was led by Arcapita Ventures, and included Boston Millennia Partners, Easton Capital Investment Group, Foundation Medical Partners, Johnson & Johnson Development Corp. and Medtronic. CardioMEMS has raised a total of $54 million since 2001 and employs 110 people. David Stern, Senior Vice President of Research and Development, accepted the award.

AtheroGenics, recognized for a partnership with London-based AstraZeneca that could be worth up to $1 billion, is an Alpharetta pharmaceutical company focused on the treatment of chronic inflammatory diseases. The collaboration with AstraZeneca is for the global development and commercialization of AtheroGenics oral drug for treatment of atherosclerosis. AtheroGenics President and CEO Dr. Russell M. Medford accepted the award.

Solvay Pharmaceuticals was recognized for the $298 million federal grant it received for development of cell-based vaccines. The Brussels-based company, with U.S. headquarters in Marietta, Ga., was awarded a five-year contract from the U.S. Department of Health and Human Services to develop cell-based influenza vaccines and plan for domestic manufacturing capacity in the U.S. Dr. Stephen Bell, U.S. Project Director for Influenza, accepted the award.

GeoVax Labs was recognized for its $4.5 million reverse merger with Dauphin Technology, enabling GeoVax to become a publicly traded company. The creative financing technique provided a rapid method of raising capital for development of GeoVax's AIDS vaccine, which is in early clinical trials. Dr. Harriet L. Robinson, chair of GeoVax's Scientific Advisory Board, and Cynthia Tolman, Vice President of Regulatory and Clinical Affairs, accepted the award. Dr. Robinson is Chief of the Division of Microbiology and Immunology at the Yerkes National Primate Research Center and is the Asa Griggs Candler Professor of Microbiology and Immunology at Emory University.

Emory University, Georgia Institute of Technology, and Medical College of Georgia (MCG), were recognized for a $10 million National Institutes of Health grant to create a Nanomedicine Development Center. The center will be based in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, and will be headed by Dr. Gang Bao, Georgia Tech College of Engineering Distinguished Professor in the Department of Biomedical Engineering. Dr. William S. Dynan, associate director of MCG's Institute of Molecular Medicine and Genetics Program and Georgia Research Alliance Eminent Scholar in Molecular Biology, is the associate director. Dr. Bao and Dr. Michael Gabridge, MCG's associate director of technology transfer and economic development, accepted the award.

About Georgia Biomedical Partnership

The Georgia Biomedical Partnership (GBP), founded in 1989, represents 280 pharmaceutical, biotech and medical device companies, universities, research institutes, government groups and other business organizations involved in the research and development of products that improve the health and quality of life of people worldwide. For more information visit

Media contact: Charles Craig, Georgia Biomedical Partnership, 404-920-2043;

CONTACT: Media, Charles Craig of Georgia Biomedical Partnership, +1-404-920-2043, or

Web site:
COPYRIGHT 2007 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 23, 2007
Previous Article:BridgePoint Medical, Inc. Raises $10 Million in Series B Financing.
Next Article:GBP Announces 2007 Biomedical Community Award Winners.

Related Articles
Serologicals Corporation CEO David A. Dodd Elected Vice Chairman of Georgia Biomedical Partnership.
Industry Leaders Salute Growth of Life Sciences at the 2002 Georgia Life Sciences Summit: From Bench to Blockbuster; President of Biotechnology...
Life Sciences Industry Leaders Salute Southeast Region at the 2003 Georgia Life Sciences Summit: The Power of Collaboration; Steven Burrill Offers...
2006 Georgia Life Sciences Summit of Advances in Biomedicine To Examine Science, Business, Finance, Public Policy Trends and Issues.
Georgia Life Sciences Summit to Feature Release of First-Ever Statewide Bioscience Industry Report.
GaTech Dean, Altea Therapeutics CEO To Receive Top GBP Awards for 2007.
GBP Announces Finalists for 2007 Deal of Year Honors.
GBP Names Melissa Wendt Emerging Leader of the Year.
GBP Announces 2007 Biomedical Community Award Winners.
GBP Applauds State Rep. Charlice Byrd for Bioeconomic Development Efforts.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters